- QIAGEN appointed Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026.
- Pratt brings over 25 years of leadership experience from companies including Filtration Group, Waters, Beckman Coulter Life Sciences, and Pall.
- The company reaffirmed its financial outlook for the third quarter and full-year 2026, and its strategic review continues.
VENLO, Netherlands — QIAGEN N.V. announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer. The appointment is effective September 1, 2026.
Pratt will succeed Thierry Bernard, who will step down as CEO and Managing Director. QIAGEN said in an emailed press release today that Bernard will support an orderly transition through the end of the year.
Leadership Transition
The Supervisory Board unanimously selected Pratt. He will also be proposed for shareholder approval as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026. Stephen H. Rusckowski, Chairman of the Supervisory Board, stated that Pratt is the right leader for QIAGEN’s next phase.
Pratt’s Background
Pratt has over 25 years of international leadership experience in life sciences, laboratory technologies, and healthcare. He most recently served as President and CEO of Filtration Group, leading the business through its sale in August 2026. His previous roles include Senior Vice President of the Waters Division at Waters Corporation and President of Beckman Coulter Life Sciences. He also held senior leadership positions at Pall Corporation. His experience spans analytical instruments, laboratory technologies, software, consumables, services, and bioprocessing applications.
Company Outlook and Strategic Review
QIAGEN reaffirmed its outlook for the third quarter and full-year 2026. The company remains focused on delivering profitable growth by advancing its growth pillars, improving operating efficiency, and allocating capital. The Supervisory Board continues to evaluate opportunities as part of its strategic review. This review aims to create value for shareholders and other stakeholders relative to QIAGEN’s standalone business plan and long-term strategic objectives.